目的 探讨血磷及相关肿瘤标志物对乳腺癌骨转移的诊断价值。方法 对2012-01到2013-01山西省肿瘤医院674份住院治疗的乳腺癌病例进行检索,并调查其基本信息资料(年龄等)、临床资料(病理类型等),实验室资料(血磷、肿瘤标志物等)。随访至2018年底按照治疗后是否发生骨转移分为两组(转移组和对照组),统计分析两组患者各项指标之间的差异。结果 治疗前,乳腺癌骨转移组与对照组血磷含量无统计学差异(t=0.768,P=0.444),而治疗后,对照组的患者其血磷水平为(1.23±0.21)mmol/L,明显高于骨转移组的(1.04±0.21)mmol/L,差异有统计学意义(t=-7.51,P=0.000)。对治疗前后的血磷水平进行配对t检验,得到同样的结果,骨转移组治疗后的血磷水平明显降低(t=2.63,P<0.05),而对照组治疗后血磷水平明显升高(t=-5.66,P<0.0001)。治疗前后骨转移组ALP、CA153、TPS水平均显著高于对照组。结论 乳腺癌患者发生骨转移后血清磷水平明显降低;ALP、CA153、TPS可以作为早期监测乳腺癌骨转移的生物学标志。
Abstract
Objective To explore the diagnostic value of serum phosphorus and some tumor markers for breast cancer (BC) bone metastasis.Methods Different clinical parameters were analyzed from the medical records of 674 patients with breast cancer in this retrospective study. Their baseline data was collected, including age, weight, height, body mass index(BMI), such laboratory markers as serum phosphorus, alkalinehosphatase(ALP), TPS, CEA, Ca199, CA125, CA153, TPS, clinical stage, and pathological test.Results There was no significant difference between the two groups(t=0.768,P=0.444) before treatment. However, serum phosphorus levels were significantly lower in patients with bone metastasis(1.04±0.21)mmol/L than in those without bone metastasis(1.23±0.21)mmol/L (t=7.51, P=0.000) after treatment. Serum phosphorus levels significantly decreased in patients with bone metastasis compared with the control, but were significantly increased after treatment in the control. The same results were obtained after paired t-test.Conclusions Serum phosphorus levels are significantly lower in patients with breast cancer bone metastasis. Serum levels of ALP, CA153 and TPS may be potential diagnostic indicators for BC bone metastasis, especially in the early stage. After treatment, the level of serum phosphorus should be monitored.
关键词
乳腺肿瘤 /
骨转移 /
血磷 /
肿瘤标志物
Key words
breast cancer /
bone metastasis /
serum phosphorus /
tumor marker
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Goretti Pinedo M, Alon U S. Erratum to: phosphate homeostasis and its role in bone health [J]. Pediatr Nephrol, 2017, 32(10): 1999.
[2] Dayanand P, Sandhyavenu H, Dayanand S, et al. Role of bisphosphonates in vascular calcification and bone Metabolism: a clinical summary[J].Curr Cardiol Rev, 2018, 14(3):192-199.
[3] De Carvalho C C, Caramujo M J. Tumour metastasis as an adaptation of tumour cells to fulfil their phosphorus requirements[J].Med Hypotheses, 2012,78(5):664-667.
[4] Kenney J M, Marinelli L D, Woodard H O. Tracer studies with radioactive phosphorus in malignant neoplastic disease [J]. Radiology, 1941, 37: 683-687.
[5] Ferreira Poloni P, Vespoli H L, Almeida-Filho B S, et al. Low bone mineral density is associated with breast cancer in postmenopausal women: a case-control study[J]. Climacteric, 2017, 20(5): 491-497.
[6] Stratton J,Hu X,Soulos P R, et al. Bone density screening in postmenopausal women with early-stage breast cancer treated with aromatase inhibitors[J], J Oncol Ract, 2017, 13(5): e505-e515.
[7] Zain N M, Seriramulu V P, Chelliah K K. Bone mineral density and breast cancer risk factors among premenopausal and postmenopausal women: a systematic review [J]. Asian Pac J Cancer Prev, 2016, 17(7): 3229-3234.
[8] Qu X, Zhang X, Qin A , et al. Bone mineral density and risk of breast cancer in postmenopausal women [J]. Breast Cancer Res Treat, 2013, 138 (1): 261-271.
[9] 梁红伟. 危重病患者早期血磷水平及其与预后的关系[J]. 现代诊断与治疗, 2013, 24(9): 2042-2043.
[10] Christensen C , Cronin-Fenton D, Frslev T, et al. Change in bone mineral density during adjuvant chemotherapy for early-stage breast cancer [J]. Support Care Cancer, 2016, 24(10):4229-4236.
[11] Axelsen C T,Jensen A B,Jakobsen E H,et al. Bone loss during neo adjuvant/adjuvant chemotherapy for early stage breast cancer: a retrospective cohort study [J]. Mol Clin Oncol, 2018, 8(6): 767-772.
[12] Sapio L, Naviglio S. Inorganic phosphate in the development and treatment of cancer: a Janus Bifrons?[J]. World J Clin Oncol, 2015, 6(6): 198-201.
PDF(511 KB)
